This site uses cookies to improve your experience.

We use necessary cookies to make our site work. We would also like to set optional analytics cookies to help us improve our site by anonymously collecting and reporting information on how you use it. For more information on how these cookies work, please see our Cookie policy.

Vision Fund investment portfolio company ArsenalBio's logo

ArsenalBio is fighting cancer by developing next generation T cell therapies.

Leadership
Ken Drazan
Fund
SVF2
Status
Private
Sector
Health Tech
Region
EMEA
Insights
Q&A
Ken Drazan: Building an LLM that speaks the language of the immune system

How ArsenalBio is targeting cancers and accelerating the speed of biomedical research

Roundup
Data and ML are creating a golden age of drug discovery

The biotech sector is poised to reap the benefits of the AI revolution, with lifesaving effects